SCHEMBL4483092

SCHEMBL4483092

CCCC[Sn](CCCC)(CCCC)c1cnc(-c2ccc(C(F)(F)F)cc2)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ADORA3 P0DMS8 3/20 0.38
TLR8 Q9NR97 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
KIF11 P52732 2/20 0.36
TRPV3 Q8NET8 4/20 0.36
RARB P10826 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478503 0.82 RAB9A (0.46) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10
SCHEMBL7792042 0.80 LMNA (0.41) KDM4ESMN1; SMN2TLR8ALDH1A1MEN1
SCHEMBL10604244 0.78 RARB (0.54) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10
SCHEMBL10602210 0.77 RARB (0.52) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10
SCHEMBL8332757 0.77 RARB (0.59) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10
SCHEMBL10602751 0.75 RARB (0.62) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10
SCHEMBL10603518 0.75 RARB (0.58) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10
SCHEMBL10605932 0.74 RARB (0.60) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10
SCHEMBL9351455 0.74 CTSS (0.46) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10
SCHEMBL2272078 0.74 RARB (0.41) RAB9ANPC1KDM4ESMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP RAB9A 2000/4885NPC1 2243/4885KDM4E 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.